In vitro assays to predict drug sensitivity and drug resistance William L McGuireDavid H KernLarry M Weisenthal Viewpoints Pages: 7 - 21
Expression of p21ras gene products in breast cancer relates to histological types and to receptor and nodal status Patrizia QuerzoliElisabetta MarchettiItalo Nenci Report Pages: 23 - 30
Correlation of aromatase activity with histological differentiation of breast cancer — A morphometric analysis Allan LiptonRichard J. SantenFrancis E. Sharkey Report Pages: 31 - 35
Invasive apocrine carcinoma of the breast: A long term follow-up study of 34 cases E. S. G. d'AmoreM. J. Terrier-LacombeG. Contesso Report Pages: 37 - 44
EGF binding is quantitatively related to growth in node-positive breast cancer Eva SpitzerKarla KoepkeRichard Grosse Report Pages: 45 - 49
Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer — A randomized study Sandra M. SwainSeth M. SteinbergMarc E. Lippman Report Pages: 51 - 57
Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice Hiroshi NagasawaMakoto AokiMasahiro Ishida Report Pages: 59 - 66
Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients H. J. HelinJ. J. IsolaH. Adlercreutz Report Pages: 67 - 73
Influence of adjuvant tamoxifen on blood lymphocytes Samuel RotsteinHenric BlomgrenLars-Victor von Stedingk Brief communication Pages: 75 - 79
Comment on ‘Difference between R5020 and the anti progestin RU486 in antiproliferative effects on human breast cancer cells’ M. R. MoooreP. GillH. Rochefort Correspondence Pages: 81 - 82
Brain metastases from breast cancer may respond to endocrine therapy Ramón ColomerDarío CasasLuis Salvador Correspondence Pages: 83 - 86
